217 results about "Somatostatin" patented technology

The present invention provides a compound of the formula:wherein Ar represents an aromatic group which may be substituted;X represents methylene, S, SO, SO2 or CO;Y represents a spacer having a main chain of 2 to 5 atoms;n represents an integer of 1 to 5;i) R1 and R2 each represents a hydrogen atom or a lower alkyl which may be substituted,ii) R1 and R2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, oriii) R1 or R2 together with -(CH2)n-N= form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;Ring A represents an aromatic ring which may be substituted;Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,with a proviso that X represents S, SO, SO2 or CO when Ring A has as a substituent a group represented by the formula:where R11 represents alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula:where R12 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof; which has an excellent somatostatin receptor binding inhibition action.

Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N^α(ω-functionalized) amino acids constructed to include a spacer and a terminal functional group. One or more of these N^α(ω-functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is specifically exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.

Disclosed are peptide agents and uses thereof that are analogs of biologically active peptides such as somatostatin and bombesin. The compounds of the invention have the general formula X-Y-Z-Q, where X is a cytotoxic agent, therapeutic agent, detectable label or chelating group, and Q is a biologically active peptide. In peptide agents of the invention Y is optionally a hydrophilic polymer or peptide, and Z is a linking peptide bonded to Q at the amino terminus of Q, having two, three, four, or five, amino acid residues selected to link X to Q, while retaining the biological activity of Q. Methods of using these peptide agents in the diagnosis and treatment of diseases are also disclosed.

The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patient.

The invention provides peptide derivatives designed to deliver peptides having growth factor inhibitory activity, especially somatostatin analogs, to the retina by sequential metabolism. The peptide derivatives, which comprise a dihydropyridine<CUSTOM-CHARACTER FILE="US06440933-20020827-P00900.TIF" ALT="custom character" HE="20" WI="20" ID="CUSTOM-CHARACTER-00001"/>pyridinium salt-type redox targetor moiety, a bulky lipophilic function and an amino acid/dipeptide/tripeptide spacer, are used in the prevention and treatment of diabetic retinopathy.

Compounds having somatostatin activity of the following Formula I,

wherein,

• • R¹ is aryl, substituted-aryl, and aryl-(lower-alkyl)-;
  • R² is lower alkyl, amino substituted lower alkyl, -carboxy-(lower-alkyl), -carbamic acid-(lower-alkyl) and -carboxy-(lower-alkyl)-aryl; and
  • R³ and R⁴ are independently, lower-alkyl, aryl, substituted-aryl, (substituted-aryl)-(lower-alkyl)-, heteroaryl, (heteroaryl)-(lower-alkyl)-, substituted-heteroaryl, (substituted heteroaryl)-(lower-alkyl)-, heterocyclic, heterocyclic-(lower-alkyl)-, substituted-heterocyclic, (substituted-heterocylic)-(lower alkyl)-, -carboxy-(lower-alkyl), and -carboxy-(lower-alkyl)-aryl; or a pharmaceutically acceptable, ester, ether, or salt thereof; methods for their use; and preparation.

Analogs of SRIF which are selective for SSTR4 in contrast to the other cloned SRIF receptors are useful in determining tissue and cellular expression of the receptor SSTR4 and its biological role in regulating tumor growth. SRIF analog peptides, such as des-AA^{1,2,4,5,12,13}[Ala⁷]-SRIF; des-AA^{1,2,4,5,12,13}[Aph⁷]-SRIF, des-AA^{1,2,4,5,12,13}[Aph⁷]Cbm-SRIF; des-AA^{1,2,4,5,12,13}[Tyr²,Ala⁷]-Cbm-SRIF, and des-AA^{1,2,4,5,12,13}[Tyr⁷,C^βMe-L-2Nal⁸]-SRIF, and counterparts incorporating D-Cys³ and/or D-Trp⁸ and/or Ala¹¹, bind with high affinity to the cloned human receptor SSTR4 and activate the receptor, but they do not bind with significant affinity to human SSTR1, SSTR2, SSTR3 or SSTR5. By incorporating an iodinated tyrosine in position-2 in these SSTR4-selective SRIF analogs, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, cytotoxins or highly radioactive elements can be N-terminally coupled or complexed thereto.

Claimed are a series of somatostatin agonists and uses thereof, according to formula (I),

A¹-cyclo[Cys-A²-D-Trp-A³-A⁴-Cys]-A⁵-Y¹,   (I)

wherein A¹, A², A³, A⁴, A⁵ and Y¹ are as defined in specification provided that the amine nitrogen of at least one peptide bond is substituted with a methyl group or pharmaceutically acceptable salts thereof.

The inventions provide compositions and methods for nucleic acid delivery comprising IIPMA conjugated to a polyamine. These compositions have the benefit of the steric hindrance of HPMA and the nucleic acid binding capability of a polyamine. Useful polyamines for this purpose include spermine, spermidine and their analogues, and DFMO. These polyamines have the ability not only to bind nucleic acids, but also have anti-cancer effects themselves. The compounds provided can also include ligand binding domains, such as vascular endothelial growth factors, somatostatin and somatostatin analogs, transferring, melanotropin, ApoE and ApoE peptides, von Willebrand's factor and von Willebrand's factor peptides, adenoviral fiber protein and adenoviral fiber protein peptides, PD 1 and PD 1 peptides, EGF and EGF peptides, RGD peptides, CCK peptides, antibody and antibody fragments, folate, pyridoxyl and sialyl-LewisX and chemical analogs. Methods for using these compositions to achieve a therapeutic effect, including for vaccination, are also provided.

Described herein are methods and devices for infusion of a radioactive compound, such as yttrium-90 radiolabeled somatostatin peptide or analog. A radiation shield defining a shielded cavity suitable for storing a radioactive substance includes a first aperture providing external access to the shielded cavity and a second aperture suitable for transferring a dosage vial into and out of the shielded cavity. A removable shielded plug and panel are adapted to shield respective apertures of the radiation shield. At least one dose of a radiolabeled compound stored in a vial in the radiation shield is delivered through a fluid communication channel at a rate of about 500 mL/hour. The fluid communication channel is washed after delivery, such that the process substantially reduces radiation exposure during infusion of the radiolabeled compound into a patient.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and/or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

A pharmaceutical composition has a therapeutically effective amount of at least one of: a pharmaceutically active nasal peptide, its pharmaceutically acceptable salt and its peptidic fragment. The composition also contains an absorbefacient effective amount of THAM in a pharmaceutically acceptable, aqueous liquid diluent or carrier. The composition is provided in a convenient form for nasal administration. In one embodiment, the peptidic fragment may be selected physiologically active lymphokines and monokines, peptidic enzymes, proteic vaccines, peptidic toxoids and personalized proteins derived from genoma. In another embodiment, the peptidic fragment may be selected from the peptide hormones and hormone antagonists buserelin, desmopressin, vasopressin, angiotensin, felypressin, octreotide, somatropin, thyrotropin (TSH), somatostatin, gosereline, thryptorelin and insulin selected from the group consisting of cow and pig, synthetic and recombinant.

The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.

The invention relates to a liquid phase synthetic method for somatostatin, which is as follows: firstly, four segment peptides of Thr(Bzl)-Phe-Thr(Bzl)-Ser(Bzl)-Cys(MeOBzl)-Bzl, Boc- Phe-Trp-Lys(z)-OH, Boc-Asn-Phe-OH and Boc-Ala-Gly-Cys(MeOBzl)-Lys(z)-OH are respectively and total synthesized; and then EDCI/HOBt is used for fragment condensation to synthesize total protective reducibility tetradecapeptide; protecting groups possessed by trifluoromethanesulfonic acid and methyl-phenoxide system de-peptide chain are used for obtaining reducibility somatostatin which is oxidized to obtain somatostatin crude product; the somatostatin crude product is separated and purified by a C18 preparative column, is frozen and dried to obtain the somatostatin.

SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.

Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1.

The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I,

where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and th compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

The invention discloses a preparation method of tetradecapeptide somatostatin. The method comprises the following steps: DCC and 3-(diethoxyphosphoryl)-1,2,3,-phentriazine-4-ketone are taken as condensing agents for preparing an intermediate a, the DCC is taken as a condensing agent for preparing an intermediate b, and the intermediate b and an intermediate c are condensed by taking diphenylphosphorylazide as a condensing agent to obtain an intermediate d; and the intermediate a and the intermediate b are condensed to obtain the tetradecapeptide somatostatin. The preparation method has the advantages of complete peptide linkage, mild operating condition, simple and practical purification, high yield, high optical activity and high chemical purity of the target product tetradecapeptide somatostatin. The yield of the target product tetradecapeptide somatostatin is 8-10% based on tyrosine methyl ester.